Literature DB >> 8264549

pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin.

D Siegel1, H Beall, M Kasai, H Arai, N W Gibson, D Ross.   

Abstract

Mitomycin C and porfiromycin were found to inactivate rat hepatic DT-diaphorase. Inactivation was pH dependent; little inactivation was detected at pH 5.8, but inactivation increased as the pH was raised to 7.8. Inactivation was concentration and time dependent and displayed pseudo-first-order kinetics. Inactivation was NADH dependent, indicating that reductive metabolism was necessary for inhibition. [3H]Mitomycin C was covalently bound to DT-diaphorase during inhibition, and the stoichiometry for inactivation of DT-diaphorase by mitomycin C was approximately 0.8 nmol of mitomycin C bound/nmol of enzyme. A higher molecular mass product (60 kDa) was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis of DT-diaphorase preincubated with NADH and mitomycin C at pH 7.8, suggesting that mitomycin C is capable of cross-linking DT-diaphorase. The kinetics of inhibition, requirement for NADH for inhibition, covalent binding of [3H] mitomycin C to DT-diaphorase, and approximate 1:1 stoichiometry suggest that this inactivation process may be mechanism based. Inhibition of DT-diaphorase by mitomycin C and porfiromycin is not limited to a cell-free system and could also be observed in HT-29 cells in culture at pH 7.2. Bioactivation of mitomycin C or porfiromycin by DT-diaphorase is favored at lower pH, whereas at higher pH values enzyme alkylation and inactivation of DT-diaphorase occur. These data suggest that the success of attempts to exploit the elevated DT-diaphorase content of certain human tumors for improved chemotherapeutic response using mitomycin C or porfiromycin will depend on intracellular pH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264549

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Mitomycinoid alkaloids: mechanism of action, biosynthesis, total syntheses, and synthetic approaches.

Authors:  Phillip D Bass; Daniel A Gubler; Ted C Judd; Robert M Williams
Journal:  Chem Rev       Date:  2013-05-08       Impact factor: 60.622

3.  Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Yasunobu Matsuda; Pavel V Korita; Masaaki Takamura; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  Int J Clin Exp Pathol       Date:  2011-04-10

4.  Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein.

Authors:  M He; P J Sheldon; D H Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

Review 5.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

6.  Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.

Authors:  D Jamieson; A T Y Tung; R J Knox; A V Boddy
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

7.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

8.  Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.

Authors:  William Atiomo; Mohamad Nasir Shafiee; Caroline Chapman; Veronika M Metzler; Jad Abouzeid; Ayşe Latif; Amy Chadwick; Sarah Kitson; Vanitha N Sivalingam; Ian J Stratford; Catrin S Rutland; Jenny L Persson; Niels Ødum; Pablo Fuentes-Utrilla; Jennie N Jeyapalan; David M Heery; Emma J Crosbie; Nigel P Mongan
Journal:  Clin Endocrinol (Oxf)       Date:  2017-08-18       Impact factor: 3.478

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.